Insider Purchases: Inside the Buy

Tag: BiotechInvesting

Split image showing Corcept Therapeutics stock volatility: one side with a red falling chart and FDA rejection stamp, the other with a green rising chart and glowing biotech lab vial, symbolizing high-risk, high-reward biotech investing.

CORT Stock 2026: FDA Rejection, Insider Buying… and a Brewing Short Squeeze?

Corcept Therapeutics just got hit with an FDA rejection—but insiders are buying millions and short interest is surging. With a profitable base business and major 2026 catalysts ahead, CORT may be one of the most explosive “binary bets” in biotech today.

Read entire article

Tags: Biotech Investing, Biotech Picks, Biotech Stocks, BiotechGrowth, BiotechInvesting, BiotechStocks, buy or sell CORT, Corcept Therapeutics, CorceptTherapeutics, CORT, CORT stock, FDA rejection, featured-insiders, FUNanc1al investing, Growth stocks, Healthcare investing, High risk high reward, hub-insiders, Insider buying, InsiderTrading, OvarianCancerResearch, Relacorilant, risks buying CORT, Short squeeze, ShortSqueeze, Stock analysis 2026, StockMarket2026, why buy CORT
A cartoon hospital tower made of money and stethoscopes, with dollar bills floating down as smiling investors in lab coats wave buy orders. Title reads: “Healthpeak: When Doctors Buy In”.

Healthpeak Properties (DOC): Insiders Are Buying—Should You?

📈 Healthpeak Properties (DOC) insiders are buying—and not just a little. But with a forward P/E north of 70 and a few post-merger integration challenges, is this stock still a hidden gem or more of a polished maybe? Dive in for the full take.

Read entire article

Tags: BiotechInvesting, DividendStocks, DOC, Funanc1al, Funanc1al Insider Series, Funanc1alDiversification, Funanc1alEdge, Funanc1alFinance, Funanc1alFun, Funanc1alHumor, Funanc1alInvesting, Funanc1alRealEstate, Funanc1alStocks, HealthcareStocks, Healthpeak, InsiderBuying, Investing, REITs, StocksToWatch
Quanterix stock infographic with insider buying highlights, biotech platform icons, and cash flow risk symbols

Quanterix Insiders Are Buying. Should You?

Quanterix insiders are buying, and institutions are still in. But revenue is sliding, and losses are deep. A potential comeback or another biotech burn? 🔬💸

Read entire article

Tags: BiotechInvesting, CashBurn, Funanc1al, Funanc1al Edge, Funanc1al for Investors, Funanc1al Insider Series, Funanc1al Investing, Funanc1alEdge, Funanc1alFun, Funanc1alInvesting, Funanc1alStocks, InsiderBuying, LifeSciences, MergersAndAcquisitions, QTRXStock, Quanterix, RiskyPlays
Cartoon-style illustration of Ligand Pharmaceuticals' building transforming into a giant molecule, with a Nasdaq bell ringing above and two smiling executives tossing cash into a biotech flask labeled “Royalty Engine.”

Ligand Pharmaceuticals (LGND): In a League of Its Own? Insiders Think So!

Ligand Pharma (LGND) isn’t chasing moonshots—it’s collecting royalties across a sprawling biotech empire. With both the CEO and CFO buying in, and a royalty engine showing 46% revenue growth, insiders may know something. Is this the most compelling quiet biotech turnaround on the Nasdaq?

Read entire article

Tags: BiotechHumor, BiotechInvesting, CEO Buys, CEO insider buying, CEOConfidence, CFO Bought Shares, CFO Insider Buying, CFOBuyIn, ContrarianStocks, Funanc1al, Funanc1al for Investors, Funanc1al Investing, Funanc1alInvesting, InsiderBuys, LGND, LGND Stock, LigandPharma, MoleculeMoney, NasdaqBell, PharmaRoyalties, RoyaltyBiotech, RoyaltyEngine, ScienceStocks, SpeculativeBiotech, TurnaroundPlays, VikingTherapeutics, WallStreetHedgeFunds, ZELSUVMI